Short answer
Scholar Rock Holding Corp (SRRK) filed an 8-K current report with the SEC on September 15, 2026 reporting Item 7.01 (Regulation FD Disclosure). FDA approved ISEMBYLD for spinal muscular atrophy patients aged 2 and older receiving SMN2-targeted treatment.
Scholar Rock Holding Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- FDA approved ISEMBYLD for spinal muscular atrophy patients aged 2 and older receiving SMN2-targeted treatment
- Management corrected prior statement: FDA requires a pregnancy safety study covering complications and birth outcomes
- FDA also requested 15-day alert reporting for domestic and foreign fracture cases
- Post-marketing commitments add safety-monitoring obligations and potential compliance costs after approval
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Scholar Rock Holding Corp 8-K filings
Get the next SRRK 8-K as it lands
Follow SRRK for push alerts, or ask the research agent what this filing means.